What we're reading, September 19, 2016: the government update rules on reporting clinical trial findings; hospitals say they aren't receiving discounts for Valeant's heart drugs; and the FDA approved the first treatment for Duchenne muscular dystrophy.
Universities and institutions that do not comply with new policies to make findings from clinical trials more widely available could find they are losing out on funding. According to The Washington Post, the government has unveiled new rules to encourage more participation in research and to spread those findings faster. The updated rules echo a threat Vice President Joe Biden made in June regarding the research findings for the Cancer Moonshot initiative. The new rules from HHS also include a need for more information on research that failed to achieve goals.
Valeant Pharmaceuticals said it would give discounts to hospitals for 2 heart drugs, but some hospitals say they haven’t seen a reduction in cost for these expensive treatments. Hospitals have reported a number of issues including not knowing to negotiate for the discounts instead of receiving them automatically, reported Bloomberg. Valeant’s CEO said it possible some hospitals using group purchasing organizations simply haven’t had the discounts passed along to them yet, but that all hospitals are eligible for the discounts and should be receiving them.
The FDA has approved the first drug to treat Duchenne muscular dystrophy. The agency overruled medical staffers who earlier this year questioned the effectiveness of the drug, according to STAT. However, the FDA has acknowledged the unmet need of patients with this rare disease. Sarepta Therapeutics will have to conduct a 2-year trial to verify the clinical benefit, and the FDA could withdraw approval if the trial ultimately fails.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More